Literature DB >> 25043977

Identification of important residues of insulin-like peptide 5 and its receptor RXFP4 for ligand-receptor interactions.

Xin-Yi Wang1, Yu-Qi Guo2, Xiao-Xia Shao2, Ya-Li Liu3, Zeng-Guang Xu3, Zhan-Yun Guo4.   

Abstract

Insulin-like peptide 5 (INSL5) is an insulin/relaxin superfamily peptide involved in the regulation of glucose homeostasis by activating its receptor RXFP4, which can also be activated by relaxin-3 in vitro. To determine the interaction mechanism of INSL5 with its receptor RXFP4, we studied their electrostatic interactions using a charge-exchange mutagenesis approach. First, we identified three negatively charged extracellular residues (Glu100, Asp104 and Glu182) in human RXFP4 that were important for receptor activation by wild-type INSL5. Second, we demonstrated that two positively charged B-chain Arg residues (B13Arg and B23Arg) in human INSL5 were involved in receptor binding and activation. Third, we proposed probable electrostatic interactions between INSL5 and RXFP4: the B-chain central B13Arg of INSL5 interacts with both Asp104 and Glu182 of RXFP4, meanwhile the B-chain C-terminal B23Arg of INSL5 interacts with both Glu100 and Asp104 of RXFP4. The present electrostatic interactions between INSL5 and RXFP4 were similar to our previously identified interactions between relaxin-3 and RXFP4, but had subtle differences that might be caused by the different B-chain C-terminal conformations of relaxin-3 and INSL5 because a dipeptide exchange at the B-chain C-terminus significantly decreased the activity of INSL5 and relaxin-3 to receptor RXFP4.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electrostatic interaction; INSL5; Ligand–receptor interaction; Mutagenesis; RXFP4

Mesh:

Substances:

Year:  2014        PMID: 25043977     DOI: 10.1016/j.abb.2014.07.010

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

Review 1.  Relaxin family peptides: structure-activity relationship studies.

Authors:  Nitin A Patil; K Johan Rosengren; Frances Separovic; John D Wade; Ross A D Bathgate; Mohammed Akhter Hossain
Journal:  Br J Pharmacol       Date:  2017-01-19       Impact factor: 8.739

2.  The actions of relaxin family peptides on signal transduction pathways activated by the relaxin family peptide receptor RXFP4.

Authors:  Sheng Y Ang; Dana S Hutchinson; Bronwyn A Evans; Mohammed A Hossain; Nitin Patil; Ross A D Bathgate; Martina Kocan; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-26       Impact factor: 3.000

3.  A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function.

Authors:  Ruslan V Pustovit; Xiaozhou Zhang; Jamie Jm Liew; Praveen Praveen; Mengjie Liu; Ada Koo; Lalita Oparija-Rogenmozere; Qinghao Ou; Martina Kocan; Shuai Nie; Ross Ad Bathgate; John B Furness; Mohammed Akhter Hossain
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-30

4.  Mechanism for insulin-like peptide 5 distinguishing the homologous relaxin family peptide receptor 3 and 4.

Authors:  Meng-Jun Hu; Xiao-Xia Shao; Jia-Hui Wang; Dian Wei; Yu-Qi Guo; Ya-Li Liu; Zeng-Guang Xu; Zhan-Yun Guo
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

5.  Development of a selective agonist for relaxin family peptide receptor 3.

Authors:  Dian Wei; Meng-Jun Hu; Xiao-Xia Shao; Jia-Hui Wang; Wei-Han Nie; Ya-Li Liu; Zeng-Guang Xu; Zhan-Yun Guo
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

6.  Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model.

Authors:  Brett Vahkal; Sergey Yegorov; Chukwunonso Onyilagha; Jacqueline Donner; Dean Reddick; Anuraag Shrivastav; Jude Uzonna; Sara V Good
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-14       Impact factor: 5.555

7.  Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling.

Authors:  Shi-Bing Li; Yan-Yan Liu; Li Yuan; Ming-Fang Ji; Yu-Ming Zheng; Zhi-Qiang Ling; Jian-Hua Sui; Mu-Sheng Zeng; Ao Zhang; Hui-Yu Li; Lin-Quan Tang; Shuo-Gui Fang; Hua Zhang; Shan Xing; Man-Zhi Li; Qian Zhong; Shao-Jun Lin; Wan-Li Liu; Peng Huang; Yi-Xin Zeng
Journal:  EMBO Mol Med       Date:  2020-07-12       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.